K
Kyle L. Kolaja
Researcher at Hoffmann-La Roche
Publications - 62
Citations - 4367
Kyle L. Kolaja is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Dieldrin & Induced pluripotent stem cell. The author has an hindex of 29, co-authored 61 publications receiving 4052 citations. Previous affiliations of Kyle L. Kolaja include Indiana University & Pfizer.
Papers
More filters
Journal ArticleDOI
High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents
Junyi Ma,Liang Guo,Steve Fiene,Blake D. Anson,James A. Thomson,Timothy J. Kamp,Kyle L. Kolaja,Bradley J. Swanson,Craig T. January +8 more
TL;DR: Detailed electrophysiological characterization of highly pure hiPSC-derived cardiomyocytes concludes that they have ionic currents and channel gating properties underlying their APs and EADs that are quantitatively similar to those reported for human cardiac myocytes.
Journal ArticleDOI
The role of oxidative stress in chemical carcinogenesis.
James E. Klaunig,Yong Xu,Jason S. Isenberg,Stephen Bachowski,Kyle L. Kolaja,Jiazhong Jiang,Donald E. Stevenson,Earl F. Walborg +7 more
TL;DR: A potential role for oxidative-induced injury in the cancer process specifically during the promotion stage is supported and the effect of nongenotoxic carcinogens may be amplified in rodents but not in primates because of rodents' greater sensitivity to ROS.
Journal ArticleDOI
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.
Thomas Force,Kyle L. Kolaja +1 more
TL;DR: It is hoped that a thorough understanding of the mechanisms underlying cardiotoxicity will lead to the development of safe, effective drugs and consequently, fewer costly surprises as agents progress through clinical trials.
Journal ArticleDOI
Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
Brigitte Ganter,Stuart Tugendreich,Cecelia Pearson,Eser Ayanoglu,Susanne Baumhueter,Keith A. Bostian,Lindsay Brady,Leslie J. Browne,John T. Calvin,Gwo-Jen Day,Naiomi C. Breckenridge,Shane Dunlea,Barrett P. Eynon,L. Mike Furness,Joe Ferng,Mark R. Fielden,Susan Y. Fujimoto,Li Gong,Christopher Hu,Radha Idury,Michael S.B. Judo,Kyle L. Kolaja,May D Lee,Christopher McSorley,James M. Minor,Ramesh V. Nair,Georges Natsoulis,Peter Nguyen,Simone M. Nicholson,Hang Pham,Alan H. Roter,Dongxu Sun,Siqi Tan,Silke Thode,Alexander M. Tolley,Antoaneta Vladimirova,Jian Yang,Zhiming Zhou,Kurt Jarnagin +38 more
TL;DR: It is demonstrated that gene expression events monitored in the liver can be used to predict pathological events occurring in that tissue as well as in hematopoietic tissues.
Journal ArticleDOI
Estimating the Risk of Drug-induced Proarrhythmia using Human Induced Pluripotent Stem Cell Derived Cardiomyocytes
Liang Guo,Rory Abrams,Joshua E. Babiarz,Jennifer D. Cohen,Sei Kameoka,Martin Sanders,Eric Chiao,Kyle L. Kolaja +7 more
TL;DR: The first published report of a high-throughput functional assay employing a monolayer of beating human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) is described, detailing a model that accurately detects drug-induced cardiac abnormalities.